Innate Pharma S.A. (IPHA) shares declined 6.50% in after-hours on Friday, September 03, 2021, and closed the weekly trading at $5.75. However, in the regular trading session of Friday, IPHA’s stock gained 47.13%. The stock volume remained 40.26 million shares, which was higher than the average daily volume of 1.28 million shares within the past 50 days. IPHA shares have fallen 3.76% over the last 12 months, and they have moved up 74.22% in the past week. Over the past three months, the stock has gained 63.56%, while over the past six months, it has jumped 37.58%.
Let’s have a look at its recent news and developments.
Upcoming ANKET presentation
On September 02, 2021, Innate Pharma SA (IPHA) announced oral presentations at the ESMO 2021 Virtual Congress, which is scheduled on September 18, 2021, at 1:30 p.m. CEST.
Innate will present pre-clinical data from its next-generation, proprietary, multi-specific NK cell engager platform known as ANKETTM (Antibody-based NK cell Engager Therapeutics).
IPHA participation in the upcoming investor conferences
- Innate Pharma S.A. will participate at Goldman Sachs 11thAnnual Biotech Symposium, which is to be held on September 07, 2021.
- IPHA will be presented at Citi 16thAnnual Biopharma Virtual Conference which is scheduled for September 08-09, 2021.
- The company will also participate in H.C.Wainwright 23rdAnnual Global Investment Conference which is to be held on September 13, 2021.
IPHA provide shares update
On August 11, 2021, Innate Pharma SA (IPHA) provided an update about its total number of shares outstanding as well as its voting rights as of August 1, 2021.
The complete details are available on the company’s website.
IPHA update about C5aR1 antibody trial
On July 6, 2021, Innate Pharma SA (IPHA) announced that FORCE, the investigator-sponsored, Phase 2 clinical trial evaluating the safety and efficacy of its anti-C5aR1 antibody, avdoralimab, in COVID-19 patients with severe pneumonia, did not meet its primary endpoints in all three cohorts of the trial.
IPHA update about TELLOMAK Trial
On June 22, 2021, Innate Pharma SA (IPHA) announced preliminary data from the mycosis fungoides (MF) cohort of the Phase 2 TELLOMAK clinical trial, evaluating lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, in an oral presentation at the 16th International Conference on Malignant Lymphoma (16-ICML).
Lacutamab demonstrated clinical responses in patients with MF that express KIR3DL2 (cohort 2), reaching the pre-determined threshold to advance to stage 2.
IPHA ANKET™ data presentation
On June 10, 2021, Innate Pharma SA (IPHA) presented the latest preclinical data from its next-generation, proprietary, multi-specific NK cell engager platform known as ANKET™ (Antibody-based NK cell Engager Therapeutics) at the Federation of Clinical Immunology Societies (FOCIS) meeting.
In preclinical studies, tetra-specific ANKET demonstrated in vitro the ability to induce human NK cell proliferation, cytokine production, and cytolytic activity against cancer cells expressing the targeted antigen.
Conclusion
IPHA stock went up after the company announced its upcoming presentation on September 18, but there was no reason behind its loss in the after-hours on Friday. Let’s see how it commence the new trading week on Tuesday, after the long weekend.
